Hanmi to reinforce injectable anticancer drug lines.

Hanmi announced recently to launch 2 injectable anti-cancer drugs such as Gembin (Gemcitabine) for the indication of non-small cell lung, bladder and pancreatic cancers and Inotecan (Irinotecan) in April and Liplatin (Oxaliplatin)

Gemcitabine bulk production was patented by Hanmi, first in Korea and proved of its efficacy and safety through clinical studies.

Inotecan, a first generic dru...